Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: For Recipients Clear all
Completed Phase 4 Interventional Results available

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

NCT00206076
View directory record Official record
Conditions
Liver Disease
Interventions
mycophenolate mofetil
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 2 Interventional

Defibrotide Dose-escalation for SOS Post-HSCT

NCT05987124
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus, anti-thymocyte globulin
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

NCT02495077
View directory record Official record
Conditions
Kidney Transplant
Interventions
Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Jul 22, 2026, 10:53 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

NCT04508907
View directory record Official record
Conditions
Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
Interventions
Mavyret
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

NCT03339401
View directory record Official record
Conditions
Adenovirus
Interventions
Standard of Care, Brincidofovir
Other · Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months to 25 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 4 Interventional

Natrecor for Pulmonary Hypertension in Lung Transplants

NCT00205426
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Natrecor
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 22, 2026, 10:53 AM EDT
Completed No phase listed Observational

Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients

NCT04130685
View directory record Official record
Conditions
Pancreas Transplant Rejection, Kidney Transplant Rejection
Interventions
Allosure Test
Diagnostic Test
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Not applicable Interventional

Respiratory Strength Training in Heart Transplant Recipients

NCT06190171
View directory record Official record
Conditions
Dysphagia, Heart Transplant Recipients
Interventions
Active respiratory muscle strength training, Sham respiratory muscle strength training
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

NCT03395405
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Nitazoxanide, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Chicago, Illinois • Kansas City, Kansas • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Completed No phase listed Observational

Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

NCT05255445
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Pediatric Cancer
Interventions
Red Blood Cell (RBC) Transfusion
Biological
Lead sponsor
Westat
Other
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Working Toward Wellness

NCT00694681
View directory record Official record
Conditions
Depression
Interventions
Telephonic care management
Behavioral
Lead sponsor
MDRC
Other
Eligibility
18 Years to 65 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation

NCT02088931
View directory record Official record
Conditions
Late Complication From Kidney Transplant
Interventions
Treg infusion
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 4 Interventional

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

NCT05626530
View directory record Official record
Conditions
Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
Interventions
Letermovir
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT03802695
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Interventions
OrcaGraft (Orca-Q)
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
12 Years to 78 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Duarte, California • Sacramento, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Physical Activity Intervention for Hematopoietic Cell Transplant Recipients and Caregivers

NCT05208554
View directory record Official record
Conditions
Hematopoietic Cell Transplant
Interventions
Integrated health counseling and step prescription
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Pheonix, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

NCT03363945
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
MDR-101
Biological
Lead sponsor
Medeor Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Loma Linda, California • Los Angeles, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Not listed Phase 2 Interventional

Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant

NCT00472329
View directory record Official record
Conditions
Graft Failure
Interventions
Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
Procedure · Drug
Lead sponsor
Colorado Blood Cancer Institute
Other
Eligibility
18 Years to 74 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting No phase listed Observational

Immune Registry for BK in Kidney Transplant Recipients

NCT06538961
View directory record Official record
Conditions
BK Virus Infection, Kidney Transplant; Complications
Interventions
Blood samples: Main Study group, Data Collection, Urine Sample- Main Study group, Urine sample- Sub-study group, Blood sample: Sub-study group
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Enrolling by invitation No phase listed Observational

Predicting Mortality in Kidney Transplant Recipients

NCT06531967
View directory record Official record
Conditions
Death
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years to 100 Years
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 3 Interventional

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

NCT06798909
View directory record Official record
Conditions
Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases
Interventions
Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 4 Interventional

Pilot Study for HLA Identical Living Donor Renal Transplant Recipients

NCT00352092
View directory record Official record
Conditions
Renal Transplant
Interventions
calcineurin inhibitor, sirolimus, mycophenolate mofetil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Early Phase 1 Interventional

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

NCT07244419
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Graft Failure
Interventions
Emapalumab 3 mg/kg, Emapalumab 10 mg/kg
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

NCT02269150
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell
Interventions
fecal microbiota transplantation (FMT), No fecal microbiota transplantation (FMT), routine management
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 22, 2026, 10:53 AM EDT